dystrophic epidermolysis bullosa treatment
May 06, 2025
Abeona Secures FDA Nod for ZEVASKYN, the First Gene Therapy for RDEB; AbbVie Gains FDA Approval for RINVOQ in Giant Cell Arteritis; Lantern Pharma Advances LP-184 with IND Clearance for TNBC Trial; Ichnos Glenmark Earns FDA Fast Track for ISB 2001 in Multiple Myeloma; Rezolute Wins Breakthrough Therapy Designation for Ersodetug in Tumor-Induced Hypoglycemia
FDA Approves Abeona’s ZEVASKYN as First Cell-Based Gene Therapy for RDEB The FDA approved Abeona Therapeutics’ ZEVASKYN (prademagene zamikeracel, or pz-cel), the first and only autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is d...
Read More...
Mar 25, 2024
Gene Therapies for Epidermolysis Bullosa Treatment: The Next Frontier in Dermatology
Epidermolysis bullosa is a genetic skin condition marked by severe skin sensitivity and the formation of blisters even from minor friction or injury. This disorder arises from genetic changes that impact the proteins crucial for upholding the skin’s structural strength. The degree of severity in epidermolysis bullo...
Read More...
Jun 16, 2023
Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?
Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into ...
Read More...
Aug 08, 2022
Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epidermolysis Bullosa Treatment Market?
Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history and low healing rates. Despite current management therapies, the disease has the potential to become severe and devastating for many patients over time. Dystrophic epidermolysis bullosa is classified into six types: dominant dyst...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
